SYNI Stock Overview
A product-based biopharmaceutical company, develops diagnostic tests and drugs to identify and treat diabetic patients at high risk for the development of cardiovascular disease. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Synvista Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.0001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 0% |
| 3 Year Change | n/a |
| 5 Year Change | 9,900.00% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| SYNI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 0.7% | 0.7% |
| 1Y | 0% | 2.8% | 23.9% |
Return vs Industry: SYNI underperformed the US Pharmaceuticals industry which returned 2.8% over the past year.
Return vs Market: SYNI underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| SYNI volatility | |
|---|---|
| SYNI Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SYNI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine SYNI's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | n/a | n/a | n/a |
Synvista Therapeutics, Inc., a product-based biopharmaceutical company, develops diagnostic tests and drugs to identify and treat diabetic patients at high risk for the development of cardiovascular disease. The company’s products include ALT-2074, a glutathione peroxidase mimetic in Phase II clinical trials for the treatment of diabetic patients with Hp2-2; and Alagebrium chloride or alagebrium, an Advanced Glycation End-product Crosslink Breaker in Phase II clinical trials for the treatment of diastolic heart failure and diabetic nephropathy. It is also developing a diagnostic test to identify and treat patients with diabetes who are in risk of cardiovascular disease.
Synvista Therapeutics, Inc. Fundamentals Summary
| SYNI fundamental statistics | |
|---|---|
| Market cap | US$258.00 |
| Earnings (TTM) | -US$19.80m |
| Revenue (TTM) | US$54.73k |
0.0x
P/S Ratio0.0x
P/E RatioIs SYNI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SYNI income statement (TTM) | |
|---|---|
| Revenue | US$54.73k |
| Cost of Revenue | US$0 |
| Gross Profit | US$54.73k |
| Other Expenses | US$19.86m |
| Earnings | -US$19.80m |
Last Reported Earnings
Sep 30, 2008
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did SYNI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 01:04 |
| End of Day Share Price | 2024/11/11 00:00 |
| Earnings | 2008/09/30 |
| Annual Earnings | 2007/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Synvista Therapeutics, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rahul Jasuja | MDB Capital Group LLC |
| Ashok Kumar | Rodman & Renshaw, LLC |